Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

September 2, 2017

Primary Completion Date

October 28, 2019

Study Completion Date

October 31, 2019

Conditions

AstheniaCancer

Interventions

OTHER

Nuvastatic TM (C5OSEW5050ESA) 1000 mg

Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.

Trial Locations (1)

Notrox Research Pvt Ltd, Bangalore